tiprankstipranks
Trending News
More News >

Liquidia falls after Insmed’s TPIP meets endpoints in study

Shares of Liquidia (LQDA) are down $4.22, or 23%, to $13.80 in pre-market trading after Insmed (INSM) announced positive topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder, or TPIP, administered once daily in patients with pulmonary arterial hypertension.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1